Nephrogenic Systemic Fibrosis (NSF) Lawsuit

Send to Friend | Bookmark | Live Chat

Nephrogenic Systemic Fibrosis (NSF) is a serious, life-threatening skin disorder, which has recently been linked to the use of gadolinium-based contrast agents during MRI or MRA procedures.

What is Nephrogenic Systemic Fibrosis?

Nephrogenic Systemic Fibrosis (NSF), also known as Nephrogenic Fibrosing Dermopathy (NFD), is a skin condition that is often described as a swelling and tightening of the skin, usually limited to the extremities. The condition may develop over a short period of days or could take weeks to fully develop. Severely affected patients may be unable to walk, or fully extend the joints of their arms, hands, legs, and feet. Complaints of muscle weakness are common.

Signs and Symptoms of Nephrogenic Systemic Fibrosis

People that have developed Nephrogenic Systemic Fibrosis generally exhibit the following symptoms:

• Burning
• Itching
• Swelling
• Hardening and tightening of the skin
• Red or dark patches on the skin
• Yellow spots on the whites of the eyes
• Stiffness in joints and trouble moving or straightening the arms, hands, legs, or feet
• Pain deep in the hip bones or ribs
• Muscle weakness
  

Treatment Options

According to The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR), “there is no consistently successful treatment for NSF, improving renal function (due to any modality) seems to slow or arrest NSF (and in many cases allows for gradual reversal of the process over time).”

Nephrogenic Systemic Fibrosis treatments that have been tried and continue to be investigated include:

• Oral steroids (prednisone)
• Topical Dovonex (under occlusion)
• Extracorporeal photopheresis (ECP)
• Plasmapheresis
• Cytoxan
• Thalidomide
• Ultraviolet therapy
• Physical therapy (PT)
• Pentoxifylline (PXF)
• High Dose Intravenous Ig Therapy
• Renal transplantation

Just Added - Over 30 New Gadolinium NSF/NFD Articles

Click Here: MRI Contrast Agent Articles

Nephrogenic Systemic Fibrosis & Gadolinium-Based Contrast Agents

UPDATE: Read the May 23, 2007 FDA press release, "FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI Images."

The U.S. Food and Drug Administration (FDA) has requested the manufacturers of gadolinium-based contrast agents to add a new boxed warning on the product labeling because of new reports linking the agents to a life-threatening skin disorder.

The requested boxed warning would state:

“Patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as Nephrogenic Systemic Fibrosis (NSF). In addition, it would state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity.”

Do I have a Nephrogenic Systemic Fibrosis Lawsuit?

The Products Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Nephrogenic Systemic Fibrosis lawsuits. We are handling individual litigation nationwide and currently accepting new Gadolinium side effect and Nephrogenic Systemic Fibrosis cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field

Nephrogenic Systemic Fibrosis News (National)

Click here to view the list of recent Press Releases from LegalView - PR.com LegalView recently updated its Heparin information portal on the latest news regarding the contaminated batch of Heparin, which may have sickened hundreds and caused the death of up to 90 individuals. U.S. officials have sourced the contamination to ... Patients, Caregivers, and the Danger of Imaging Studies: The Four ... - Medscape News To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details ... Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media ... - PR Newswire Magnevist(R) and Ultravist(R) are part of Amerinet's Portfolio of Contracted Contrast Media WAYNE, N.J., April 8, 2008 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that the company has been ... LegalView Keeps Readers Up to Date with Recently Released Scientific ... - PR.com LegalView recently alerted readers on its mesothelioma blog, which is continually updated, that scientists are finding the presence of asbestos in everyday products. LegalView posted the findings on its mesothelioma information portal that offers a ... New Kidney Disease Can Be Fatal - Austin American-Statesman FRIDAY, Oct. 5 (HealthDay News) -- Kidney disease patients with a newly identified disease called nephrogenic systemic fibrosis (NSF) are at increased risk of death, U.S. researchers report. The researchers also concluded that exposure to gadolinium ... Medscape Alert Index - Medscape News Recalls & Warnings Black-Box Warning Added to Dexedrine Dextroamphetamine sulfate has been linked to sudden death in children being treated for attention deficit-hyperactivity disorder who have structural cardiac abnormalities or other cardiac ... MRI Dye Linked To Potentially Fatal Skin Disease - Health Talk Health Canada is advising consumers of a notice sent to Canadian hospitals advising relevant health care professionals of safety concerns related to contrast agents containing gadolinium. These contrast agents have been linked to a rare and ...

Related Websites & Recent Gadolinium Studies

5/23/07 - FDA Press Release

2/07/07 - Study Links Gadolinium treatment to NSF

1/25/07 - MRI Contrast Agent Linked to Rare Disease

1/15/07 - Dialysis to Prevent NSF After Gadolinium Treatment